Beyond Antibiotics: Bacteriophage Therapy Against Multidrug-Resistant Pathogens in the Era of Antimicrobial Resistance

Towards accurate artificial intelligence models for strain-level phage-host prediction

10.1093/bib/bbag085 · doi-reference

Giving antibiotics a second chance: evolutionary trade-offs and phage-driven restoration of antibiotic susceptibility

10.1007/s40259-026-00789-7 · doi-reference

An overview of the current state of phage therapy for the treatment of biofilm-related infections

10.1016/j.coviro.2022.101209 · doi-reference

Clinical application of customized and non-customized bacteriophage therapy in patients with refractory/resistant bacterial infections: A systematic review and meta-analysis

10.1016/j.ijantimicag.2025.107570 · doi-reference

Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections

10.1128/cmr.00044-24 · doi-reference

Towards a reference methodology for bacteriophage susceptibility testing - position paper of the EUCAST Phage Susceptibility Testing Subcommittee

10.1016/j.cmi.2026.06.005 · doi-reference

Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections

10.3389/fphar.2025.1713471 · doi-reference

Bacteriophage production in compliance with regulatory requirements

10.1007/978-1-0716-3523-0_6 · doi-reference

Regulation of phage therapy medicinal products: developments, challenges, and opportunities

10.3389/fcimb.2025.1631359 · doi-reference

Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial

10.1016/s1473-3099(20)30330-3 · doi-reference

Safety of bacteriophage therapy in severe Staphylococcus aureus infection

10.1038/s41564-019-0634-z · doi-reference

Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial

10.1016/s1473-3099(18)30482-1 · doi-reference

Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus

10.1038/s41591-019-0437-z · doi-reference

Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection

10.1128/aac.00954-17 · doi-reference

The current landscape of phage-antibiotic synergistic (PAS) interactions

10.3390/antibiotics14060545 · doi-reference

Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa

10.1038/srep26717 · doi-reference

Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process

10.1007/s00253-017-8224-6 · doi-reference

The biofilm matrix

10.1038/nrmicro2415 · doi-reference

Pharmacologically aware phage therapy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies

10.1128/mmbr.00012-19 · doi-reference

A comprehensive review on phage therapy and phage-based drug development

10.3390/antibiotics13090870 · doi-reference

Phage as a prospective arsenal against superbugs

10.1007/s11033-026-12537-9 · doi-reference

Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses

10.1016/j.lanmic.2024.100992 · doi-reference

Multidrug-resistant Gram-negative bacterial infections

10.1016/s0140-6736(24)02081-6 · doi-reference

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

10.1016/s0140-6736(21)02724-0 · doi-reference